Page last updated: 2024-10-24

positive regulation of hepatocyte proliferation

Definition

Target type: biologicalprocess

Any process that activates or increases the frequency, rate or extent of hepatocyte proliferation. [GOC:BHF, GOC:mah]

Positive regulation of hepatocyte proliferation is a complex process involving multiple signaling pathways and transcription factors that promote the growth and division of liver cells. It is essential for liver regeneration after injury, but dysregulation of this process can contribute to liver disease.

**Growth factors and signaling pathways:**

* **Hepatocyte growth factor (HGF):** A key regulator of hepatocyte proliferation, HGF binds to its receptor, c-Met, on the cell surface, activating downstream signaling pathways, including the RAS/MAPK and PI3K/AKT pathways. These pathways promote cell survival, proliferation, and migration.
* **Transforming growth factor-alpha (TGF-alpha):** Another important growth factor, TGF-alpha activates the EGFR signaling pathway, leading to similar effects as HGF.
* **Interleukin-6 (IL-6):** A cytokine involved in inflammation, IL-6 can also stimulate hepatocyte proliferation, particularly in the context of liver injury. It activates the JAK/STAT pathway.
* **Wnt signaling pathway:** This pathway plays a crucial role in development and regeneration. Wnt ligands bind to their receptors, leading to the accumulation of beta-catenin in the cytoplasm, which then translocates to the nucleus and activates target genes involved in cell proliferation and differentiation.

**Transcription factors:**

* **c-Myc:** A proto-oncogene that regulates cell cycle progression and is upregulated in response to growth factor stimulation.
* **E2F:** A family of transcription factors that control the expression of genes involved in DNA replication and cell cycle progression.
* **STAT3:** A transcription factor activated by IL-6 and other cytokines, it promotes cell survival and proliferation.
* **NF-κB:** A transcription factor involved in inflammation and immune responses. It can also regulate hepatocyte proliferation.

**Other mechanisms:**

* **Cell cycle regulation:** Positive regulation of hepatocyte proliferation involves the coordinated activation of cell cycle checkpoints and the expression of cyclin-dependent kinases (CDKs) and cyclins, which promote cell cycle progression.
* **Extracellular matrix remodeling:** The extracellular matrix surrounding hepatocytes undergoes changes during proliferation, facilitating cell migration and growth.

**Dysregulation and disease:**

* **Excessive proliferation:** Uncontrolled hepatocyte proliferation can lead to liver hyperplasia, which can predispose to liver cancer.
* **Defective proliferation:** Reduced hepatocyte proliferation can impair liver regeneration and contribute to liver fibrosis and cirrhosis.

Overall, positive regulation of hepatocyte proliferation is a complex and tightly regulated process essential for liver homeostasis. Dysregulation of this process can have significant consequences for liver health.'
"

Proteins (4)

ProteinDefinitionTaxonomy
Protein Wnt-3aA protein Wnt-3a that is encoded in the genome of human. [PRO:DNx, UniProtKB:P56704]Homo sapiens (human)
Serine protease hepsinA serine protease hepsin that is encoded in the genome of human. [PRO:DNx, UniProtKB:P05981]Homo sapiens (human)
Fibroblast growth factor 1A fibroblast growth factor 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P05230]Homo sapiens (human)
Tumor necrosis factorA tumor necrosis factor that is encoded in the genome of human. [PRO:DNx]Homo sapiens (human)

Compounds (30)

CompoundDefinitionClassesRoles
camostatcamostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.benzoate ester;
carboxylic ester;
diester;
guanidines;
tertiary carboxamide
anti-inflammatory agent;
anticoronaviral agent;
antifibrinolytic drug;
antihypertensive agent;
antineoplastic agent;
antiviral agent;
serine protease inhibitor
gabexateGabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.benzoate ester
mesalaminemesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols
non-steroidal anti-inflammatory drug
way 151693
nafamostatnafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplasticbenzoic acids;
guanidines
pentoxifyllineoxopurine
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases.methoxybenzenes
roliprampyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
sulfasalazinesulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.

Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
bergeninbergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structuretrihydroxybenzoic acidmetabolite
leupeptinaldehyde;
tripeptide
bacterial metabolite;
calpain inhibitor;
cathepsin B inhibitor;
EC 3.4.21.4 (trypsin) inhibitor;
serine protease inhibitor
marimastatmarimastat : A secondary carboxamide resulting from the foraml condensation of the carboxy group of (2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methylpentanoic acid with the alpha-amino group of N,3-dimethyl-L-valinamide.

marimastat: a matrix metalloproteinase inhibitor active in patients with advanced carcinoma of the pancreas, prostate, or ovary
hydroxamic acid;
secondary carboxamide
antineoplastic agent;
matrix metalloproteinase inhibitor
5-amidinoindole
birb 796aromatic ether;
morpholines;
naphthalenes;
pyrazoles;
ureas
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
immunomodulator
dabigatrandabigatran : An aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-beta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism.

Dabigatran: A THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.
aromatic amide;
benzimidazoles;
beta-alanine derivative;
carboxamidine;
pyridines
anticoagulant;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
EC 3.4.21.5 (thrombin) inhibitor
benzamidinecarboxamidinium ion
ganoderic acid atriterpenoid
ganoderiol fganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first sourcetriterpenoid
1-(phenylmethyl)benzimidazolebenzimidazoles
luteolin-7-glucosideluteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.

luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum
beta-D-glucoside;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone
antioxidant;
plant metabolite
apigetrinapigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.

apigetrin: structure given in first source
beta-D-glucoside;
dihydroxyflavone;
glycosyloxyflavone;
monosaccharide derivative
antibacterial agent;
metabolite;
non-steroidal anti-inflammatory drug
calycosin-7-o-beta-d-glucopyranosidecalycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage.

calycosin-7-O-beta-D-glucoside: from Radix Astragali
4'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative
spd-304SPD-304: structure in first source
ganoderic acid fganoderic acid F: isolated from Ganoderma lucidum; structure in first sourcetriterpenoid
phosphomannopentaose sulfatephosphomannopentaose sulfate: structure in first source
ganoderic acid c2ganoderic acid C2: from the fruiting body of Ganoderma; structure in first sourcetriterpenoid
pg 545PG 545: an anti-angiogenesis agent with heparanase inhibitory activity; structure in first source
CCT251545CCT251545 : A chloropyridine that is 3-chloropyridine substituted by a 1-oxo-2,8-diazaspiro[4.5]decan-8-yl group and a 4-(1-methyl-1H-pyrazol-4-yl)phenyl group at positions 4 and 5, respectively. It is an orally bioavailable inhibitor of Wnt signaling (IC50 = 5 nM) and a potent and selective chemical probe for cyclin-dependent kinases CDK8 and CDK19.

CCT251545: a Wnt signaling inhibitor; structure in first source
azaspiro compound;
chloropyridine;
pyrazoles
antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
Wnt signalling inhibitor
xav939XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group.

XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source
(trifluoromethyl)benzenes;
thiopyranopyrimidine
tankyrase inhibitor
nvp-tnks656